Intravenous Ustekinumab Reinduction Is Effective in Prior Biologic Failure Crohn's Disease Patients Already on Every-4-Week Dosing

Rocio Sedano; Leonardo Guizzetti; Cassandra McDonald; Vipul Jairath

doi:10.1016/j.cgh.2020.07.064

Intravenous Ustekinumab Reinduction Is Effective in Prior Biologic Failure Crohn's Disease Patients Already on Every-4-Week Dosing

Clin Gastroenterol Hepatol. 2021 Jul;19(7):1497-1498.e1. doi: 10.1016/j.cgh.2020.07.064. Epub 2020 Aug 4.

Authors

Rocio Sedano¹, Leonardo Guizzetti², Cassandra McDonald³, Vipul Jairath⁴

Affiliations

¹ Division of Gastroenterology, Department of Medicine, Western University, London, Ontario, Canada.
² Robarts Clinical Trials, London, Ontario, Canada.
³ Lawson Health Research Institute, Western University, London, Ontario, Canada.
⁴ Division of Gastroenterology, Department of Medicine, Western University, London, Ontario, Canada; Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada. Electronic address: [email protected].

PMID: 32763479
DOI: 10.1016/j.cgh.2020.07.064

Abstract

Ustekinumab (UST) targets the common subunit (p40) of interleukins-12/23,^1,2 approved for intravenous (IV) induction of remission in moderate-to-severe Crohn's disease (CD), followed by subcutaneous (SC) doses for maintenance of remission.^3,4 The role of IV reinduction of UST in patients already on every-4-week (Q4) maintenance with partial response or loss of response (LOR) is unclear.⁵ The aim was to assess response and remission rates for UST IV reinduction in patients with CD with partial response or LOR who already were on Q4 SC dosing and had failed prior biological therapies.

MeSH terms

Administration, Intravenous
Biological Products* / therapeutic use
Crohn Disease* / drug therapy
Humans
Remission Induction
Ustekinumab / therapeutic use

Substances

Biological Products
Ustekinumab